The demand for weight loss drugs is skyrocketing, and it's not just a trend. These medications, like Ozempic, Mounjaro, and Wegovy, are the blockbuster drugs of the modern era, with brand names that have become almost household names. Since Ozempic's launch, it has generated over €57 billion for its manufacturer, Novo Nordisk, making it a big business. But the surge in popularity has sparked a black market, with some individuals attempting to access these prescription-only drugs illegally. The British Medical Journal's recent report on a new obesity drug, retatrutide, further highlights the growing demand and the potential for misuse. The black market for these drugs is thriving, with a significant proportion of seized falsified or illegal medicines presented as GLP-1 drugs. The Health Products Regulatory Authority (HPRA) reported detaining over 48,752 units of these drugs in 2024, a stark increase from the previous year. This trend raises serious health concerns, as individuals purchasing these drugs online may not know what they are buying, leading to potential dangers. The high cost of GLP-1 drugs also drives people to alternative markets. The shift from injection to pill versions has made these drugs more accessible, but it also raises environmental concerns regarding the disposal of expired injection pens and needles. Despite the growing demand, it's crucial to consider the long-term use and effects of these drugs. While they have shown effectiveness in weight loss and managing other health issues, there is still much we don't know about their broader benefits and potential side effects. The HPRA has received over 1,500 reports of suspected adverse reactions from weight loss medication, with gastrointestinal issues, nausea, vomiting, and diarrhea being the most common side effects. Additionally, there have been nine reports of fatalities involving individuals taking anti-obesity injections, although the HPRA emphasizes that these incidents do not necessarily indicate a causal relationship. Consultant endocrinologist Donal O'Shea highlights the importance of patient supervision and counseling regarding side effects. He warns against the drugs becoming a 'runaway train' and emphasizes the need for medical supervision when using GLP-1s. The popularity of these weight-loss drugs is expected to persist, despite their high prices for private patients. Clinical trials demonstrate their effectiveness, but the question remains: can healthcare systems afford them? The growth in demand is rapid, and it will take years for cheaper generic versions to become available. The speed of weight reduction makes these drugs highly attractive, especially for those who have struggled with traditional weight loss methods. However, studies show that discontinuing GLP-1s often leads individuals to regain their original or similar weight, raising questions about long-term usage. The expectation is that the demand for weight loss medications will continue to soar, and the transition from injections to pill forms is likely to further drive this growth. Therefore, the key message is that GLP-1s should be used under medical supervision to ensure safety and effectiveness.
